Current status of anti-CD30 monoclonal
antibody therapy in anaplastic lymphoma
and Hodgkin’s lymphoma
S.J. Proctor, J. Wilkinson
Academic Haematology, Medical School, Newcastle University, Newcastle upon Tyne, United Kingdom
Until the advent of anti-CD20 antibody therapy, the mainstay of treatment in non-Hodgkin’s lymphoma (NHL) was standard chemotherapy. The combination of antibodies with chemotherapy has enhanced event-free and overall survival in both diffuse large B cell NHL and follicular NHL.1 With this example of combined chemo/ immunotherapy to enhance clinical response, it has been considered of interest to attempt a similar approach for T cell NHL and Hodgkin’s lymphoma (HL).
[>Read full article in PDF]